Fuso Pharmaceutical Faces Partial Setback in Patent Infringement Case
Pharmaceuticals

Fuso Pharmaceutical Faces Partial Setback in Patent Infringement Case

Staff Reporter 12 Views 0 Comments

Confident Investing Starts Here:

The latest update is out from Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ).

Fuso Pharmaceutical Industries, Ltd. announced that the Intellectual Property High Court partially upheld a patent infringement claim by Toray Industries, Inc. regarding their product, Nalfurafine Hydrochloride OD Tablets. The court ordered Fuso to pay damages, impacting their financial results for the fiscal year ending March 2025. Fuso plans to appeal the decision to the Supreme Court, although their financial forecast for the fiscal year ending March 2026 remains unchanged.

More about Fuso Pharmaceutical Industries,Ltd.

Fuso Pharmaceutical Industries, Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of medical products, including oral antipruritic agents.

Average Trading Volume: 24,801

Technical Sentiment Signal: Buy

Current Market Cap: Yen19.61B

For a thorough assessment of 4538 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks’

Best Online Brokers

, and find the ideal broker for your trades.

Report an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply